| 查看: 6447 | 回复: 10 | ||||||||||||||
| 当前只显示满足指定条件的回帖,点击这里查看本话题的所有回帖 | ||||||||||||||
[调剂信息]
广东医学院梁欣课题组接收调剂研究生
|
||||||||||||||
| 学校: | 广东医学院 |
| 专业: | 理学->基础医学->病理学与病理生理学 |
| 年级: | 2023 |
| 招生人数: | 1 |
| 招生状态: | 正在招生中 |
| 联系方式: | ********* (为保护个人隐私,联系方式仅限APP查看) |
补充内容
|
梁欣,女,山东日照人,博士,硕士研究生导师,现在广东医科大学生理教研室任教。先后就读于西华大学,西北大学,中国科学院大学获得学士,硕士和博士学位,在美国圣路易斯大学,清华大学深圳研究生院,中山大学进行研究工作。发表sci研究论文20余篇,以通讯作者和第一作者在nano today,acs nano, journal of controlled release, nanoscale, nano research ,journal of biological chemistry(2篇)和theranostics等国际著名学术期刊发表sci论文13篇,他引400余次,单篇论文最高引用270余次。2篇esi高被引论文。获授权发明专利3项。获2020年华夏医学科技奖三等奖,深圳市海外高层次人才,深圳市光明区紧缺人才。主要研究方向:药物递送,肿瘤免疫治疗,自身免疫性疾病(红斑狼疮)的治疗。 近5年发表的部分论文: x. liang#, l. janks#, tm egan. (2022). using whole-cell electrophysiology and patch-clamp photometry to characterize p2x7 receptor currents. in: nicke, a. (eds) the p2x7 receptor. methods in molecular biology, vol 2510:217-237. humana, new york, ny.外文参编图书 f. meng, l. li, z. zhang, z. lin, j. zhang, x. liang#, x. zhang#. biosynthetic neoantigen displayed on bacteria derived vesicles elicit systemic antitumour immunity. journal of extracellular vesicles. 11(12):e12289. (if=17.337, 中科院医学2区) zhangyan jing*, yuan li*, yumeng ma*, xiaozhou zhang, xin liang#, xudong zhang# leverage biomaterials to modulate immunity for type 1 diabetes. frontiers in immunology. 2022, 13:997287. (if=8.786, 医学2区) liyan li*, qianwei miao*, fanqiang meng*, baoqi li, tianyuan xue, tianliang fang, zhirang zhang, jinxie zhang, xinyu ye, yang kang, xingding zhang, qian chen, xin liang#, hongbo chen#, xudong zhang#. genetic engineering cellular vesicles expressing cd64 as checkpoint antibody carrier for cancer immunotherapy. theranostics. 2021, 11(12), 6033-6043. (if = 11.6,医学1区) b. li#,t. fang#, y. li#, z. zhang, l. li, f. meng, j. wang, l. hou, x. liang*, x. zhang*, z. gu*. engineered t cell extracellular vesicles displaying pd-1 boost anti-tumor immunity. nano today. 46, 2022, 101606. (if = 18.962, 中科院化学综合1区) t. xue#, z. zhang#, t. fang#, b. li, y. li, l. li, y. jiang, f. duan, f. meng*, x. liang*, x. zhang*. cellular vesicles expressing pd-1-blocking scfv reinvigorate t cell immunity against cancer. nano research. 2022, 15(6): 5295-5304. (if = 10.269,中科院材料科学1区) x. ye#, x. liang#, et al. surgical tumor-derived personalized photothermal vaccine formulation for cancer immunotherapy, acs nano, 2019, 13(3), 2956-2968. (if = 15.9, 中科院材料科学1区,esi高被引) xudong zhang*, xin liang*, jianjun gu, danfeng chang, jinxie zhang, zhaowei chen, yangqi ye, chao wang, wei tao, xiaowei zeng, gan liu, yongjun zhang, lin mei#,zhen gu#. investigation and intervention of autophagy to guide cancer treatment with nanogels. nanoscale. 20170107, 9(1):150-163. (if = 7.79, jcr一区,esi高被引,26) xinliang*, yin yang*, lijun wang*, xianbing zhu, xiaowei zeng, xiaojin wu, xudong zhang#, mei lin#. ph-triggered burst intracellular release from hollow microspheres to induce autophagic cancer cell death. journal of materials chemistry b. 20151208, 3(48): 9383-9396. (if = 6.3, jcr一区,8) xin liang, samways, ds., wolf, k., bowles, ea., richards, jp., bruno, j., dutertre, s., dipaolo rj., egan tm, quantifying ca2+ current and permeability in atp-gated p2x7 receptors. journal of biological chemistry,20150320, 290(12): 7930-7942. (if = 5.2, jcr二区,24) x. liang#, x. ye#, et al. photothermal cancer immunotherapy by erythrocyte membrane-coated black phosphorus formulation, j. controlled release, 2019, 296, 150~161. (if = 9.8, 中科院医学1区, esi高被引,2020年esi前0.1%热点论文) x. liang, samways, ds., et al., ca2+ flux through splice variants of the atp-gated ionotropic receptor p2x7 is regulated by its cytoplasmic n terminus. j. biological chemistry, 2019, 294(33), 12521-12533. (if = 5.2, 中科院生物学2区) 科研经费充足,优先招收有生物背景的同学,例如本科为:生物技术,生物工程等同学,有意愿同学请发送简历至:2176872651@qq.com 发自小木虫Android客户端 |
基础医学专业的招生信息推荐
» 猜你喜欢
职称评审没过,求安慰
已经有41人回复
回收溶剂求助
已经有7人回复
硝基苯如何除去
已经有3人回复
A期刊撤稿
已经有4人回复
垃圾破二本职称评审标准
已经有17人回复
投稿Elsevier的Neoplasia杂志,到最后选publishing options时页面空白,不能完成投稿
已经有22人回复
EST投稿状态问题
已经有7人回复
毕业后当辅导员了,天天各种学生超烦
已经有4人回复
求助文献
已经有3人回复
投稿返修后收到这样的回复,还有希望吗
已经有8人回复
» 本主题相关商家推荐: (我也要在这里推广)
4楼2023-03-22 10:08:36
2楼2023-03-22 08:57:57
3楼2023-03-22 08:57:58
5楼2023-03-22 14:53:57













回复此楼